Advanced search
Publication Cover
Future Medicinal Chemistry Volume 1, 2009 - Issue 5
Submit an article Journal homepage
161
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Concise Asymmetric Synthesis of Configurationally Stable 4-Trifluoromethyl Thalidomide

Vadim A Soloshonok1 Department of Chemistry & Biochemistry, The University of Oklahoma, Norman, OK73019, USACorrespondence[email protected]
View further author information
,
Takeshi Yamada2 Graduate School of Science, Osaka City University, Sugimoto, Sumiyoshi-ku, Osaka558-8585, JapanView further author information
,
Kazuhiko Sakaguchi2 Graduate School of Science, Osaka City University, Sugimoto, Sumiyoshi-ku, Osaka558-8585, JapanView further author information
&
Yasufumi Ohfune2 Graduate School of Science, Osaka City University, Sugimoto, Sumiyoshi-ku, Osaka558-8585, JapanCorrespondence[email protected]
View further author information
Pages 897-908 | Published online: 19 Aug 2009

Bibliography

  • Eger K , JalalianB, VerspohlEJ, LupkeNP. Synthesis, central nervous system activity and teratogenicity of a homothalidomideArzneim. Forsch.40, 1073–1075 (1990).
  • Folkman J . Tumor angiogenesis: a possible control point in tumor growth.Ann. Intern. Med.82, 96–100 (1975).
  • Sampio EP , SarnoEN, GalillyR, CohnZA, KaplanG. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytesJ. Exp. Med.173, 699–703 (1991).
  • Moreira AL , SampioEP, ZmuidzinasA, FrindtP, SmithKA, KaplanG. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradationJ. Exp. Med.177, 1675–1680 (1993).
  • Musto P , D‘AuriaF, PietrantuonoGet al. Role of thalidomide in previously untreated patients with multiple myeloma. Expert Rev. Anticancer Ther. 8, 1569–1580 (2008).
  • Hashimoto Y . Thalidomide as a multi-template for development of biologically active compounds.Arch. Pharm. Chem. Life Sci.341, 536–547 (2008).
  • Palumbo A , FaconT, SonneveldPet al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111, 3968–3977 (2008).
  • Walker SL , WatersMF, LockwoodDN. The role of thalidomide in the management of erythema nodosum leprosum.Lepr. Rev.78, 197–215 (2007).
  • Ferrara N , HillanKJ, GerberHP, NovotnyW. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.Nat. Rev. Drug Discov.3, 391–400 (2004).
  • Kumar S , RajkumarSV. Thalidomide and dexamethasone: therapy for multiple myeloma.Expert Rev. Anticancer Ther.5759–766 (2005).
  • Kumar S , AndersonKC. Drug insight: thalidomide as a treatment for multiple myeloma.Nat. Clin. Pract. Oncol.2, 262–270 (2005).
  • Eigler A , SinhaB, HartmannG, EndresS. Taming TNF: strategies to restrain this proinflammatory cytokine.Immunology Today18, 487–492 (1997).
  • Teo SK , ResztakKE, SchefflerMAet al. Thalidomide in the treatment of leprosy. Microbes Infect. 4, 1193–1202 (2002).
  • Kruse FE , JoussenAM, RohrschneiderK, BeckerMD, VolckerHE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.Graefe’s Arch. Clin. Exp. Ophthalmol.236, 461–466 (1998).
  • Bartlett JB , DredgeK, DalgleishAG. The evolution of thalidomide and its IMiD derivatives as anticancer agents.Nat. Rev. Cancer4, 314–322 (2004).
  • Singhal S , MehtaJ. Thalidomide in cancer: potential uses and limitations.BioDrugs15, 163–172 (2001).
  • Sheskin J . Thalidomide in the treatment of lepra reactions.Clin. Pharmacol. Ther.6, 303–306 (1965).
  • Blaschke G , KlaftHP, FickentscherK, KoehlerF. Chromatographic racemic separation of thalidomide and teratogenic activity of its enantiomers.Arzneim. Forsch.29, 1640–1642 (1979).
  • Hoglund P , ErikssonT, BjorkmanS. A double-blind study of the sedative effects of the thalidomide enantiomers in humans.J. Pharmacokinet. Biopharm.26, 363–383 (1998).
  • Eriksson T , BjorkmanS, RothB, FygeA, HoglundP. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality7, 44–52 (1995).
  • Wintersk W , FrankusE. Thalidomide enantiomers.Lancet339, 365 (1992).
  • Eriksson T , BjorkmanS, HoglundP. Clinical pharmacology of thalidomide.Eur. J. Clin. Pharmacol.57, 365–376 (2001).
  • Wnendt S , FinkamM, WinterW, OssingJ, RabbeG, ZwingenbergerK. Enantioselective inhibition of TNF-α release by thalidomide and thalidomide-analogs.Chirality8, 390–396 (1996).
  • Knoche B , BlaschkeG. Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography. J. Chromatogr.2, 235–240 (1994).
  • Chung F , PalmerBD, MullerGWet al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol. Res. 14, 75–82 (2003).
  • Miyachi H , KolsoY, ShiraiR, NiwayamaS, LiuJO, HashimotoY. Tumor necrosis factor-α production enhancing activity of substituted 3´-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity.Chem. Pharm. Bull.46, 1165–1168 (1998).
  • Buech HP , OmlorG, KnabeJ. Stereoselective differences of central nervous system-depressive action of a homologous series of 3-alkyl-thalidomide analysis.Arzneim. Forsch.40, 32–36 (1990).
  • Knabe J , OmlorG. Synthesis of racemates and enantiomers of 3-alkylthalidomide analogs and determination of their absolute configuration.Arch. Der Pharmazie.322, 499–505 (1989).
  • Muller GW , ChenRS. Preparation of 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione and compositions thereof for pharmaceutical applications.PCT Int. Appl.56 (2006).
  • Osipov SN , TsoukerP, HennigL, BurgerK. 3-Trifluoromethyl- and 3-difluoromethyl-thalidomides.Tetrahedron,60, 271–274 (2004).
  • Takeuchi Y , ShiragamiT, KimuraK, SuzukiE, ShibataN. (R)- and (S)-3-fluorothalidomides: isosteric analogs of thalidomide. Org. Lett.1, 1571–1573 (1999).
  • Corot C , PortM, GautheretT, WilliardX. Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic.US Pat. Appl. Publ.17 (2005).
  • Luzzio FA , ThomasEM, FiggWD. Thalidomide metabolites and analogs. Part 2: cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. Tetrahedron Lett.41, 7151–7155 (2000).
  • Yamada T , OkadaT, SakaguchiK, OhfuneY, UekiH, SoloshonokVA. Efficient asymmetric synthesis of novel 4-substituted and configurationally stable analogs of thalidomide.Org Lett.8, 5625–5628 (2006)
  • Soloshonok VA , GerusII, YagupolskiiYL, KukharVP. Fluorine-containing amino acids. III. α-trifluoromethyl-α-amino acids.Zh. Org. Khim.23, 2308–2313 (1987).
  • Soloshonok VA , AvilovDV, KukharVPet al. Asymmetric aldol reactions of chiral Ni(II)-complex of glycine with aldehydes. Stereodivergent synthesis of syn-(2S)- and syn-(2R)-β-alkylserines. Tetra. Asymm. 6, 1741–1756 (1995).
  • Soloshonok VA , AvilovDV, KukharVP Highly diastereoselective asymmetric aldol reactions of chiral Ni(II)-complex of glycine with trifluoromethyl ketones. Tetra. Asymm.7, 1547–1550 (1996).
  • Basiuk VA , GromovoyTY, ChuikoAA, SoloshonokVA, KukharVP. A novel approach to the synthesis of symmetric optically active 2,5-dioxopiperazines.Synthesis5, 449–451 (1992).
  • Soloshonok VA , KirilenkoAG, KukharVP, ResnatiG. Transamination of fluorinated β-keto carboxylic esters. A biomimetic approach to β-polyfluoroalkyl-β-amino acids.Tetrahedron Lett.34, 3621–3624 (1993).
  • Soloshonok VA , OnoT. The effect of substituents on the feasibility of azomethine-azomethine isomerization: new synthetic opportunities for biomimetic transamination.Tetrahedron52, 14701–14712 (1996).
  • Bravo P , FarinaA, FrigerioM, Valdo Meille S, Viani F, Soloshonok VA. New fluorinated chiral synthons. Tetra. Asymm.5, 987–1004 (1994).
  • Soloshonok VA , HayashiT, IshikawaK, NagashimaN. Highly diastereoselective aldol reaction of fluoroalkyl aryl ketones with methyl isocyanoacetate catalyzed by silver(I)/triethylamine.Tetrahedron Lett.35, 1055–1058 (1994).
  • Ohkura H , BerbasovDO, SoloshonokVA. Simple and highly diastereoselective synthesis of trifluoromethyl-containing myosmines via reaction between 2-(aminomethyl)pyridine and 1,1,1,5,5,5-hexafluoro-2,4-pentanedione.Tetrahedron Lett.44, 2417–2420 (2003).
  • Bravo P , FarinaA, KukharVPet al. Stereoselective additions of α-lithiated alkyl p-tolylsulfoxides to N-PMP fluoroalkyl aldimines. An efficient approach to enantiomerically pure fluoro-amino compounds J. Org. Chem. 62, 3424–3425 (1997).
  • Soloshonok VA , KacharovAD, AvilovDV, IshikawaK, NagashimaN, HayashiT. Transition metal/base-catalyzed aldol reactions of methyl α-isocyanoacetate with prochiral ketones, a straightforward approach to stereochemically defined β,β-disubstituted-β-hydroxy-α-amino acids. Scope and limitations. J. Org. Chem.62, 3470–3479 (1997).
  • Soloshonok VA , KacharovAD, HayashiT. Gold(I)-catalyzed asymmetric aldol reactions of isocyanoacetic acid derivatives with fluoroaryl aldehydes.Tetrahedron52, 245–254 (1996).
  • Soloshonok VA , KukharVP, Biomimetic transamination of α-keto perfluorocarboxylic esters. an efficient preparative synthesis of β,β,β-trifluoroalanine. Tetrahedron53, 8307–8314 (1997).
  • Soloshonok VA , YagupolskiiYL, KukharVP. Fluorine-containing amino acids. V. imines of trifluoropyruvic acid in the synthesis of n-substituted trifluoroalanines. Zh. Org. Khim.24, 1638–1644 (1988).
  • Tang X , SoloshonokVA, HrubyVJ. Convenient asymmetric synthesis of enantiomerically pure 2´6´-dimethyltyrosine (DMT) via alkylation of chiral nucleophilic glycine equivalent.Tetra. Asymm.11, 2917–2925 (2000).
  • Soloshonok VA , TangX, HrubyVJ. Large-scale asymmetric synthesis of novel sterically constrained 2´,6´-dimethyl- and α,2´,6´-trimethyltyrosine and –phenylalanine derivatives via alkylation of chiral equivalents of nucleophilic glycine and alanine. Tetrahedron57, 6375–6382 (2001).
  • Ellis TK , MartinCH, TsaiGM, UekiH, SoloshonokVA. Efficient synthesis of sterically constrained symmetrically α,α-disubstituted α-amino acids under operationally convenient conditions.J. Org. Chem.68, 6208–6214 (2003).
  • Qiu W , GuX, SoloshonokVA, CarducciMD, HrubyVJ. Stereoselective synthesis of conformationally constrained reverse turn dipeptide mimetics.Tetrahedron Lett.42, 145–148 (2001).
  • Cai M , CaiC, MayorovAVet al. Biological and conformational study of β-substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity. J. Peptide Res. 63, 116–131 (2004).
  • Soloshonok VA , TangX, HrubyVJ, MeerveltLV. asymmetric synthesis of α,β-dialkyl-α-phenylalanines via direct alkylation of chiral alanine derivative with racemic α-alkylbenzylbromides. A case of high enantiomer differentiation at room temperature.Org. Lett.3, 341–343 (2001).
  • Soloshonok VA , HayashiT. Gold(I)-catalyzed asymmetric aldol reaction of methyl isocyanoacetate with fluorinated benzaldehydes.Tetrahedron Lett.35, 2713–2716 (1994).
  • Soloshonok VA , AvilovDV, KukharVP, MeerveltLV, MischenkoN. An efficient asymmetric synthesis of (2S,3S)-3-trifluoromethylpyroglutamic acid. Tetrahedron Lett.38, 4903–4904 (1997).
  • Soloshonok VA , CaiC, HrubyVJ. Asymmetric michael addition reactions of chiral Ni(II) complex of glycine with N-(enoyl)oxazolidinones: improved reactivity and stereochemical outcome. Tetrahedron55, 12031–12044 (1999).
  • Soloshonok VA , CaiC, HrubyVJ, MeerveltLV. Asymmetric synthesis of novel highly sterically constrained (2S,3S)-3-methyl-3-trifluoromethyl- and (2S,3S,4R)-3-trifluoromethyl-4-methylpyroglutamic acids. Tetrahedron55, 12045–12058 (1999).
  • Ueki H , EllisTK, MartinCH, BoleneSB, BoettigerTU, SoloshonokVA. Improved synthesis of proline derived Ni(II)-complexes of glycine, a versatile chiral equivalents of nucleophilic glycine for general asymmetric synthesis of α-amino acids.J. Org. Chem.68, 7104–7107 (2003).
  • Soloshonok VA , CaiC, YamadaT, UekiH, OhfuneY, HrubyVJ. Michael addition reactions between chiral equivalents of a nucleophilic glycine and (S)- or (R)-3-(E-enoyl)-4-phenyl-1,3-oxazolidin-2-ones as a general method for efficient preparation of β-substituted pyroglutamic acids. Case of topographically controlled stereoselectivity. J. Am. Chem. Soc.127, 15296–15303 (2005).
  • Soloshonok VA . Highly diastereoselective michael addition reactions between nucleophilic glycine equivalents and β-substituted-α,β-unsaturated carboxylic acid derivatives; a general approach to the stereochemically defined and sterically χ-constrained α-amino acids. Current Org. Chem.6, 341–364 (2002).
  • Soloshonok VA , BelokonYN, KuzminaNAet al. Asymmetric synthesis of phosphorus analogs of dicarboxylic α-amino acids. J. Chem. Soc. Perkin Trans. 1, 1525–1529 (1992).
  • Soloshonok VA , CaiC, HrubyVJ. (S)- or (R)-N-(E-enoyl)-4-phenyl-1,3-oxazolidin-2-ones: ideal michael acceptors to afford a virtually complete control of simple and face diastereoselectivity in addition reactions with glycine derivatives. Org. Lett.2, 747–750 (2000).
  • Soloshonok VA , CaiC, HrubyVJ. Toward design of a practical methodology for stereocontrolled synthesis of χ-constrained pyroglutamic acids and related compounds. virtually complete control of simple diastereoselectivity in the michael addition reactions of glycine Ni(II) complexes with N-(enoyl)oxazolidinones. Tetrahedron Lett.41, 135–139 (2000).
  • Soloshonok VA , CaiC, HrubyVJ. A unique case of face diastereoselectivity in the michael addition reactions between Ni(II)-complexes of glycine and chiral 3-(E-enoyl)-1,3-oxazolidin-2-ones. Tetrahedron Lett.41, 9645–9649 (2000).
  • Soloshonok VA , CaiC, HrubyVJ. Asymmetric michael addition reactions of chiral Ni(II) complex of glycine with N-(enoyl)oxazolidinones: improved reactivity and stereochemical outcome. Tetra. Asymm.10, 4265–4269 (1999).
  • Soloshonok VA , UekiH, EllisTK. New generation of nucleophilic glycine equivalents.Tetrahedron Lett.46, 941–944 (2005).
  • Soloshonok VA , UekiH, EllisTK, YamadaT, OhfuneY. Application of modular nucleophilic glycine equivalents for truly practical asymmetric synthesis of β-substituted pyroglutamic acids.Tetrahedron Lett.46, 1107–1110 (2005).
  • Soloshonok VA , EllisTK. Design and synthesis of a new generation of ‘NH’ Ni(II) complexes of glycine schiff bases and their unprecedented C-H vs. N-H chemoselectivity in the alkyl halide alkylations and Michael addition reactions.Synlett533–538 (2006).
  • Ellis TK , UekiH, YamadaT, OhfuneY, SoloshonokVA. The design, synthesis and evaluation of a new generation of modular nucleophilic glycine equivalents for the efficient synthesis of sterically constrained α-amino acids.J. Org. Chem.71, 8572–8578 (2006).
  • Soloshonok VA , UekiH, JiangC, CaiC, HrubyVJ. A convenient, room temperature-organic base protocol for preparing chiral N-(enoyl)-1,3-oxazolidine-2-ones. Helv. Chim. Acta.85, 3616–3623 (2002).
  • Yamazaki T , ShinoharaN, KitazumeT, SatoS. Michael addition of organocopper species to 3-[(E)-4,4,4-trifluorobut-2-enoyl]oxazolidin-2-ones.J. Fluorine Chem.97, 91–96 (1999).
  • Cai C , SoloshonokVA, HrubyVJ. Michael addition reactions between chiral Ni(II) complex of glycine and 3-(trans-enoyl)oxazolidin-2-ones. A case of electron donor-acceptor attractive interactions-controlled face diastereoselectivity. J. Org. Chem.66, 1339–1350 (2001).
  • Kobzev SV , SoloshonokVA, GalushkoSV, YagupolskiiYL, KukharVP. Fluorine-containing amino acids. VI. Acid–base properties of α-trifluoromethyl-α-amino acids.Zh. Obshch. Khim.59, 909–912 (1989).
  • Soloshonok VA , HayashiT. Gold(I)-catalyzed asymmetric aldol reaction of fluorinated benzaldehydes with α-isocyanoacetamide.Tetra. Asymm.5, 1091–1094 (1994).
  • Tarver JE , TerranoveKM, JoullieMM. Hetero-Diels–Alder and pyroglutamate approaches to (2S,4R)-2-methylamino-5-hydroxy-4-methylpentanoic acid. Tetrahedron45, 10277–10284 (2004).
  • King FE , KiddDAA. New synthesis of glutamine and of γ-dipeptides of glutamic acid from phthalylated intermediates.J. Chem. Soc.3315–3319 (1949).
  • Krstenansky JL , del Rosario-Chow M, Currie BL. The synthesis of syn- and anti-2(S)-phthalimidomethyl-2,3,4,4α,7,7α-hexahydro-6-oxo-5H-pyrano[2,3-β]pyrroles as rigid β-bend peptide-mimetics. J. Heterocyclic Chem.29, 707–711 (1992).
  • Sakaitani M , OhfuneY. Syntheses and reactions of silyl carbamates. 1. Chemoselective transformation of amino protecting groups viatert-butyldimethylsilyl carbamates. J. Org. Chem.55, 870–876 (1990).
  • Flaih N , Pharm-HuyC, GalonsH. An expeditious synthesis of cyclic imides.Tetrahedron Lett.40, 3697–3698 (1999).
  • Nefkens GHL . Synthesis of phthaloyl amino acids under mild conditions.Nature185, 309 (1960).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.